155 related articles for article (PubMed ID: 20706875)
1. Placebo adherence and its association with morbidity and mortality in the studies of left ventricular dysfunction.
Avins AL; Pressman A; Ackerson L; Rudd P; Neuhaus J; Vittinghoff E
J Gen Intern Med; 2010 Dec; 25(12):1275-81. PubMed ID: 20706875
[TBL] [Abstract][Full Text] [Related]
2. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure.
Böhm M; Pogue J; Kindermann I; Pöss J; Koon T; Yusuf S
Eur J Heart Fail; 2014 Mar; 16(3):325-33. PubMed ID: 24464788
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.
Al-Khadra AS; Salem DN; Rand WM; Udelson JE; Smith JJ; Konstam MA
J Am Coll Cardiol; 1998 Feb; 31(2):419-25. PubMed ID: 9462588
[TBL] [Abstract][Full Text] [Related]
5. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
Jong P; Yusuf S; Rousseau MF; Ahn SA; Bangdiwala SI
Lancet; 2003 May; 361(9372):1843-8. PubMed ID: 12788569
[TBL] [Abstract][Full Text] [Related]
6. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
Szucs TD; Goedde M; Berger K; Kiowski W
Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy.
Greenberg B; Quinones MA; Koilpillai C; Limacher M; Shindler D; Benedict C; Shelton B
Circulation; 1995 May; 91(10):2573-81. PubMed ID: 7743619
[TBL] [Abstract][Full Text] [Related]
8. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD).
Knight EL; Glynn RJ; McIntyre KM; Mogun H; Avorn J
Am Heart J; 1999 Nov; 138(5 Pt 1):849-55. PubMed ID: 10539815
[TBL] [Abstract][Full Text] [Related]
9. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).
Vermes E; Ducharme A; Bourassa MG; Lessard M; White M; Tardif JC;
Circulation; 2003 Mar; 107(9):1291-6. PubMed ID: 12628950
[TBL] [Abstract][Full Text] [Related]
10. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators.
Konstam V; Salem D; Pouleur H; Kostis J; Gorkin L; Shumaker S; Mottard I; Woods P; Konstam MA; Yusuf S
Am J Cardiol; 1996 Oct; 78(8):890-5. PubMed ID: 8888661
[TBL] [Abstract][Full Text] [Related]
11. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
Dries DL; Exner DV; Gersh BJ; Domanski MJ; Waclawiw MA; Stevenson LW
J Am Coll Cardiol; 1998 Sep; 32(3):695-703. PubMed ID: 9741514
[TBL] [Abstract][Full Text] [Related]
12. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials.
Vermes E; Tardif JC; Bourassa MG; Racine N; Levesque S; White M; Guerra PG; Ducharme A
Circulation; 2003 Jun; 107(23):2926-31. PubMed ID: 12771010
[TBL] [Abstract][Full Text] [Related]
13. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.
Lam PH; Dooley DJ; Fonarow GC; Butler J; Bhatt DL; Filippatos GS; Deedwania P; Forman DE; White M; Fletcher RD; Arundel C; Blackman MR; Adamopoulos C; Kanonidis IE; Aban IB; Patel K; Aronow WS; Allman RM; Anker SD; Pitt B; Ahmed A
Eur J Heart Fail; 2018 Feb; 20(2):359-369. PubMed ID: 28980368
[TBL] [Abstract][Full Text] [Related]
14. The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited.
Parker AB; Yusuf S; Naylor CD
Am Heart J; 2002 Dec; 144(6):941-7. PubMed ID: 12486418
[TBL] [Abstract][Full Text] [Related]
15. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators.
Rogers WJ; Johnstone DE; Yusuf S; Weiner DH; Gallagher P; Bittner VA; Ahn S; Schron E; Shumaker SA; Sheffield LT
J Am Coll Cardiol; 1994 Feb; 23(2):393-400. PubMed ID: 8294693
[TBL] [Abstract][Full Text] [Related]
16. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction.
Exner DV; Dries DL; Domanski MJ; Cohn JN
N Engl J Med; 2001 May; 344(18):1351-7. PubMed ID: 11333991
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in the outcome of left ventricular dysfunction.
Dries DL; Exner DV; Gersh BJ; Cooper HA; Carson PE; Domanski MJ
N Engl J Med; 1999 Feb; 340(8):609-16. PubMed ID: 10029645
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction.
Ishani A; Weinhandl E; Zhao Z; Gilbertson DT; Collins AJ; Yusuf S; Herzog CA
J Am Coll Cardiol; 2005 Feb; 45(3):391-9. PubMed ID: 15680718
[TBL] [Abstract][Full Text] [Related]
19. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial.
Bowling CB; Sanders PW; Allman RM; Rogers WJ; Patel K; Aban IB; Rich MW; Pitt B; White M; Bakris GC; Fonarow GC; Ahmed A
Int J Cardiol; 2013 Jul; 167(1):151-6. PubMed ID: 22257685
[TBL] [Abstract][Full Text] [Related]
20. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.
McMurray J; Packer M; Desai A; Gong J; Greenlaw N; Lefkowitz M; Rizkala A; Shi V; Rouleau J; Solomon S; Swedberg K; Zile MR; Andersen K; Arango JL; Arnold M; Bĕlohlávek J; Böhm M; Boytsov S; Burgess L; Cabrera W; Chen CH; Erglis A; Fu M; Gomez E; Gonzalez A; Hagege AA; Katova T; Kiatchoosakun S; Kim KS; Bayram E; Martinez F; Merkely B; Mendoza I; Mosterd A; Negrusz-Kawecka M; Peuhkurinen K; Ramires F; Refsgaard J; Senni M; Sibulo AS; Silva-Cardoso J; Squire I; Starling RC; Vinereanu D; Teerlink JR; Wong R;
Eur Heart J; 2015 Feb; 36(7):434-9. PubMed ID: 25416329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
